The True Monthly Cost of GLP-1: Beyond the Sticker Price

A GLP-1 provider's advertised price may cover only the first month, starting dose or medication itself. To budget for treatment, check the ongoing price, dose-related increases and required fees. Then calculate the total for the period you expect to use the service.

When the starter price rises

The most common gap between advertised and actual cost is the intro rate. A provider advertises, say, $99 for your first month, and the price steps up to $199 from month two onward. Do the math: month one at $99 plus eleven months at $199 is about $2,290 for the year — an effective average of roughly $191 per month, nearly double the number that got you in the door. A truly flat price, like the one CoreAge Rx publishes, costs the same in month twelve as in month one, which is why price transparency is a weighted factor in our methodology. When you compare providers, compare the month-twelve price, not the month-one hook. Two examples in our published reviews: The Edit's $200 semaglutide is a first-month price sitting in front of a standing $259, and Lighter You leads with a $99 that matches no program it sells. Telos Rx illustrates why both figures matter: on its oral tirzepatide plans it prints the first month and the standing rate side by side — $49 then $129 on the longest plan, $199 then $229 with no commitment — while every injectable card quotes only a struck-through intro figure and will not name a standing price until you are inside the intake. If only the introductory price is published, ask for the ongoing rate before paying.

Check the billing period

Some advertised rates use a different billing period from the one a reader may expect. Luvo Health charges every four weeks, so what reads as $249 a month is thirteen charges across a calendar year rather than twelve — roughly one extra payment you did not budget for. The same page headlines "Starting at $45/week", which is its 52-week prepay total divided out, not a rate anyone pays week to week. Before you compare any two providers, confirm you are comparing the same unit: a four-week charge, calendar-month charge and 90-day supply cover different periods.

Does your price rise with your dose?

GLP-1 medications are not started at the full dose. In the pivotal semaglutide trial, the dose was titrated up over about 16 weeks to reach the 2.4 mg target¹, and tirzepatide is similarly escalated over months in its trial program² — see the exact FDA-labeled titration schedule for both molecules. This affects cost because some providers price by dose: the low sticker is the starting dose, and your cost rises as you titrate toward a therapeutic level. With flat pricing across doses, an increase in dose does not raise the medication charge. With dose-tiered pricing, the maintenance cost can be higher than the starting price. Always ask what the price is at the dose you will actually maintain. Tirzepatide in particular carries its own annual math worth isolating — see the cheapest tirzepatide over a full year for the molecule-specific ranking.

Add the required fees

The medication price is not always the whole bill. Watch for a separate initial consultation fee, ongoing membership or coaching subscriptions that cannot be unbundled, lab charges, and shipping. Some of these add real value; the problem is only when they are not disclosed up front. A bundled coaching subscription you cannot cancel independently is both a cost and a flexibility hit — it shows up in our contract-flexibility scoring for that reason. If insurance covers part of your bill, the fees that survive prior authorization are a separate wildcard worth checking — see GLP-1 insurance coverage and prior authorization for what typically does and doesn't get approved, and Medicare, Medicaid and HSA/FSA rules if a government payer or a tax-advantaged account is part of your specific math.

How do you calculate your true monthly cost?

Put it together into one number:

For a plan billed once per calendar month, with one starter month followed by eleven maintenance months:

True annual cost = (month-one price) + (11 × maintenance-dose monthly price) + (one-time fees) + (recurring monthly non-medication fees × 12)

This formula assumes calendar-month billing. Four-week plans create 13 medication charges in a 52-week model; package plans require their actual duration and payment terms. Do not apply twelve payments to every offer.

Then divide by 12 for your true monthly cost. Which price you feed in matters as much as the formula: where a provider publishes two rates for the same product, use the rate that matches your intended commitment — a provider that prints both a subscribe price and a no-commitment price is showing you a $20-to-$30 monthly gap and letting you choose which one to budget. Compare the resulting totals across your shortlist; starter prices alone leave out later increases and dose tiers. The cost calculators do this arithmetic for you, and the compare tool shows published prices and billing terms side by side.

Budget for the treatment period and the commitment

The useful comparison is the period you and your clinician are planning, plus what happens if the plan changes. Treatment duration varies; an annual estimate is a budgeting model, not a requirement to buy or use a medicine for a year. The monthly versus prepaid plans guide separates an advertised average from the money due today and the portion that may not be refundable.

If cost threatens continuity, discuss options with the prescriber before changing treatment. Stopping does not mean every benefit disappears immediately, although weight regain after treatment ends is documented and deserves planning.

Use our full-year GLP-1 comparison for disclosed modeled costs, then check current required fees, dose terms and cancellation rules. Partners are listed first as a group; the methodology explains the Index and placement. A low modeled cost does not establish that a particular medicine is suitable for you. The monthly cost guide, cash-pay overview and comparison workspace help you investigate a shortlist rather than treating one headline number as the whole decision.